GOSS
Calendar ping: Q1 is coming
Gossamer Bio is officially on deck. The company said it will report first-quarter 2026 financial results on Monday, May 18, and management will host a live conference call and webcast afterward.
Why investors should care
This is the kind of biotech update that can quietly matter a lot. Gossamer is still in the clinical-stage arena, so the real question isn’t just what happened with revenue — it’s whether the company can keep advancing seralutinib without burning through its runway like a freshman with a new credit card.
What to watch in the call
- Any fresh clues on seralutinib development for PAH and PH-ILD
- Cash burn and how long the balance sheet can support the pipeline
- Whether management sounds more confident, or more “please hold for the next slide”
Big picture: earnings schedule headlines can look like calendar fluff, but for small-cap biotech, the next data point can be the one that tells you whether the story still has legs.